New pill shows promise for Tough-to-Treat lymphoma
NCT ID NCT07545603
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called XNW5004 in 65 people with follicular lymphoma (a slow-growing blood cancer) that has returned or stopped responding to at least three prior treatments. Participants take the drug twice daily for 28-day cycles. The main goal is to see how many patients have their tumors shrink or disappear. This is not a cure, but aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA GRADE 3 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospitial
RECRUITINGBeijing, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune-Guiding antibody aims to clean up remaining cancer cells after transplant
- Promising combo for lymphoma hits early snag – trial stopped
- Could fewer zaps do the job? new trial tests low-dose radiation for lymphoma
- New CAR T-Cell therapy SynKIR-310 enters first human trial for Tough-to-Treat lymphoma
- Is 'Watch and Wait' really 'Worry and Wait'? new study investigates